ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0094

Black Patients Are Less Satisfied with the Hospital Experience After Primary Hip and Knee Arthroplasty
Abstract Number: 0095

Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis
Abstract Number: 0096

Delayed Referral of Female Rheumatoid Arthritis Patients: Where Are We Now? A Study Spanning Three Decades
Abstract Number: 0097

Sex and Race/ethnicity Differences in Knee Symptoms, Function, and Radiographic Features: Preliminary Descriptive Data from the Johnston County Health Study
Abstract Number: 0098

Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 0099

Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
Abstract Number: 0100

COVID Vaccinations in Patients with Rheumatologic Diseases- perspectives and Disparities in a Safety-net Tertiary Care Hospital in Memphis, Tennessee
Abstract Number: 0101

Twenty-five Years of Mortality Data in Those with Lower Extremity Osteoarthritis: The Role of Socioeconomic Status
Abstract Number: 0102

Impact of Racial Implicit Bias on Juvenile Idiopathic Arthritis Patients’ Treatment Recommendations
Abstract Number: 0103

Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
Abstract Number: 0104

Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumatology-Focused Journals
Abstract Number: 0105

Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
Abstract Number: 0106

A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
Abstract Number: 0107

Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil
Abstract Number: 0108

Study of the Level of Antibody Response to COVID-19 Vaccine in a Minority Population with Rheumatological Disorders

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].